Raykov Rosty's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Nov 9, 2023
- Accession no.
- 0001415889-23-014958
- Filed
- Nov 9, 2023
- Trade date
- Nov 8, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $194.3K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Raykov RostyCIK 0001468316 | Director, Officer (CHIEF EXECUTIVE OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 8, 2023 | Common shares | SSaleDisposed | −17,049 | $7.69 | −$131,106.81 | 290,582 | Direct | |
| Nov 8, 2023 | Common shares | SSaleDisposed | −7,995 | $7.90 | −$63,160.5 | 282,587 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.